Response Genetics Signs Collaboration Agreement With Hitachi Chemical To Provide Diagnostic Testing Services To Asia-Pacific

Los Angeles,CA - Response Genetics, Inc. recently announced that it has entered into a collaboration agreement with Hitachi Chemical Co., Ltd., a leading diagnostics manufacturer in Japan. Under the terms of this agreement, Hitachi Chemical will begin using the Company's proprietary and patented techniques to extract genetic information from formalin-fixed paraffin-embedded (FFPE) tissue samples collected in Southeast Asia, Australia and New Zealand. As part of this collaboration agreement, Response Genetics will provide Hitachi Chemical with the technical information and assistance necessary to perform the testing services, and the two Companies will divide the revenues. Also under the terms of the agreement, Hitachi Chemical intends to introduce Response Genetics to potential new testing services customers in the region to expand the testing of FFPE clinical samples in Asia.

"We are delighted to be partnering with the well-known diagnostics company Hitachi Chemical in three key markets, Southeast Asia, Australia and New Zealand," said Kathleen Danenberg, President and CEO of Response Genetics. "This collaboration is part of our global strategy to provide diagnostic testing services to pharmaceutical companies conducting clinical studies worldwide."

The Southeast Asian countries covered under this agreement include Japan, North Korea, South Korea, Taiwan, Mongolia, Pakistan, Bangladesh, Sri Lanka, Nepal, Singapore, Malaysia, Indonesia, Brunei, Thailand,Myanmar, Laos, Cambodia, Vietnam and the Philippines.

SOURCE: Response Genetics, Inc.